Physician profile
Vaishali Doshi
NPI 1922198407
$8,686.39
in general payments reported to CMS, 2019-2025
55 companies · $480 in 2025
The $480 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,743 · 2020: $1,134 · 2021: $1,932 · 2022: $998 · 2023: $1,027 · 2024: $1,373 · 2025: $480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,879.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $850.09 | 2019-2025 | Lynparza, Tagrisso, Enhertu |
| Merck Sharp & Dohme LLC | $713.55 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Amgen INC. | $671.94 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $545.27 | 2021-2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $468.71 | 2019-2025 | |
| Seagen INC. | $462.10 | 2020-2023 | Tukysa |
| E.R. Squibb & Sons, L.L.C. | $395.85 | 2019-2025 | Opdualag |
| Daiichi Sankyo INC. | $323.98 | 2020-2024 | Enhertu, Vanflyta |
| Celgene Corporation | $303.57 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Incyte Corporation | $262.18 | 2019-2022 | |
| Pfizer INC. | $256.92 | 2019-2025 | |
| Genentech USA, INC. | $255.14 | 2019-2024 | Alecensa, Tecentriq, Rozlytrek |
| Janssen Biotech, INC. | $254.85 | 2019-2022 | |
| Eisai INC. | $253.29 | 2019-2023 | |
| Intera Oncology, INC | $196.38 | 2025 | Intera |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vaishali Doshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.